Many anti-cancer therapies can induce or enhance the immunogenic cell death (ICD), a process that releases damage-associated molecular patterns (DAMPs) to prime antigen processing and presentation necessary for successful cancer immunotherapy. However, the clinical potential of these therapies, especially the chemotherapy, is limited by serious systemic side effects, because of their non-specific accumulation out of the tumors. Nanosized drug delivery systems (NDDSs) can improve the specificity of anti-cancer therapies, which enhance ICD in the tumor while alleviating toxicities. In this review, we summarize recent progress of ICD-inducing NDDSs with a focus on their enhanced safety and efficacy for cancer immunotherapy.

许多抗癌疗法可诱导或增强免疫原性细胞死亡（ICD），该过程可释放损伤相关分子模式（DAMP），以引发成功的抗原加工和成功进行癌症免疫治疗所必需的呈递。然而，这些疗法的临床潜力，尤其是化学疗法，由于其在肿瘤外的非特异性蓄积，受到严重的全身性副作用的限制。纳米级药物递送系统（NDDSs）可以提高抗癌疗法的特异性，从而增强肿瘤中的ICD，同时减轻毒性。在这篇综述中，我们总结了诱导ICD的NDDSs的最新进展，重点是其增强的癌症免疫疗法安全性和有效性。